Company: PRGO
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001585364-25-000014
Chunk: 41

Company: PERRIGO Co plc
Filing Date: 2025-02-28
Form: 10-K
Item: Item 7
Chunk 41
---
$98.7 million decrease in operating expenses due primarily to lower selling and administrative costs of $149.4 million due primarily to Project Energize and lower variable employee costs. These decreases were partially offset by increased restructuring expense of approximately $68 million and higher advertising and promotion costs compared to the prior year. 

CONSUMER SELF-CARE AMERICAS

Segment Financial Results

Year Ended(in millions, except percentages)December 31, 2024December 31, 2023Net sales$2,693.7 $2,962.3 Gross profit$779.1 $908.4 Gross profit %28.9 %30.7 %Operating income $269.9 $389.6 Operating income %10.0 %13.2 %

Net sales decreased $268.6 million, or 9.1% primarily due to:

•$253.0 million decrease, or 8.6%, due primarily to $178.3 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health category, primarily driven by new product sales of Opill®; and

•$15.1 million decrease from exited product lines. 

CSCA net sales by product category were as follows:

SalesYear Ended(in millions, except percentages)December 31, 2024December 31, 2023(1) $ Change% ChangeUpper Respiratory$500.3 $561.4 $(61.1)(10.9)%Digestive Health497.4 507.5 (10.1)(2.0)%Nutrition449.5 563.2 (113.7)(20.2)%Pain and Sleep-Aids345.5 397.2 (51.7)(13.0)%Healthy Lifestyle306.8 311.4 (4.6)(1.5)%Oral Care275.4 310.4 (35.0)(11.3)%Skin Care220.1 240.5 (20.4)(8.5)%Women's Health81.